Definium Therapeutics Reports Positive Phase 3 Results for DT120
Definium Therapeutics reported positive Phase 3 results for DT120 in generalized anxiety disorder.
Related stories
Voyager Technologies Wins $35M NASA HUNCH Management Contract
Voyager Technologies was awarded a five-year contract to manage NASA’s HUNCH program, extending a role it has held since 2021.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC
NHPC Q2 consolidated revenue from operations at 44.83 billion rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
MGE Energy Reports Q3 2026 Operating Revenue of $190.4 Million
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
US Equity Futures Rise Pre-Bell as Traders Assess Midterm Election Results
US equity futures rose before the bell as traders assessed the implications of a Democratic win in the US midterm elections.
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
NHPC Reports Q2 Consolidated Net Profit of 15.49 Billion Rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
Pliant Raises $80 Million in Series C Funding
Seaya Nova and Speedinvest led the oversubscribed round. Pliant is opening its commercial payments infrastructure to AI agents.
L impact | EQUITY | Nov 04, 2026, 01:59 PM UTC